Sanofi-Aventis at peer perform by Bear Stearns

Sanofi-Aventis was rated at peer perform by Bear Stearns analyst Alexandra Hauber on news of the Plavix settlement with Apotex., allowing market entry for Apotex eight months early (September 2011 vs. May 2012). The deal is not done yet, as objections can still be filed. The analyst increased its fair value estimate for Sanofi-Aventis to €80 per share. Shares of the Paris-based pharmaceutical company were up $4.20, or 9.62%, at $47.88 on volume of 4,445,300 shares versus the three-month running average of 1,585,060 shares. (NYSE: SNY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.